Negative prognostic impacts of increased ID-1 expression have been shown in breast cancers (Schoppmann et al, 2003), pancreatic cancers (Lee et al, 2004), melanoma (Straume and Akslen, 2005), cervical cancers (Schindl et al, 2001), and ovarian carcinomas (Schindl et al, 2003). This evidence concerns the gene ID1 and familial pancreatic carcinoma.